DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Aktueller Standort:
> This Story

Log in oder Register to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

NYC proton facility opens for business $300 million dollar, 140,000 square-foot facility was ten years in the making

Bill aiming to reduce prior authorization delays for cancer treatment introduced in Congress Supporting timely access to care

Roche and GE Healthcare release NAVIFY Tumor Board 2.0 Supports personalized treatment decision-making

Cancer mortality for men, women and children on the decline, says report Decreased by 1.8 percent in men and 1.4 percent in women

FDA okays Philips' MR-only radiotherapy simulator, MRCAT pelvis Create treatment plans for bladder, rectal, anal and cervical cancer

Japanese startup to develop ultra-compact proton therapy system Designed to replace conventional radiotherapy systems

Varian to acquire Cancer Treatment Services International for $283 million Enables production of multidisciplinary solutions

Varian acquires CyberHeart, enters cardiac radioablation market Emerging technology could benefit treatment of irregular heartbeats

New 12-year study highlights value of PRRT, based on long-term outcomes Understanding peptide receptor radionuclide therapy

Korean cancer center aims to deploy heavy ion therapy in 2022 Plans also call for the onboarding of more CR and MR systems

Timothy J. Rozelle

Using ERISA to end proton therapy denials

By Timothy J. Rozelle and Lisa S. Kantor, Kantor & Kantor, LLP (Northridge, CA)

The Employee Retirement Income Security Act of 1974 (ERISA) is a confusing set of federal laws that offer limited relief for health care consumers. ERISA’s implementing regulations place little pressure, and nearly incentivize, employer-funded plans or health insurers to shirk their claims handling responsibilities. The lack of real punitive consequence for procedural violations under ERISA favors the suppression of claims and appeals, effectively shutting the doors to enforcement in federal court. Considering that 49 percent of Americans are covered by health insurance obtained through an employer, it is important to understand the pitfalls of ERISA.

ERISA appears to pose a bleak statutory vehicle for patients diagnosed with cancer seeking coverage for prescribed proton therapy cancer treatment. In fact, the vast majority of claim denials, according to most estimates, are never appealed. Of those appealed, less than half are overturned in favor of the insured.
Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

Many of the independent review organizations, (such as Medical Review Institute of America, Advanced Medical Reviews and AllMed Healthcare Management, Inc. to name just a few) that conduct external reviews for state insurance or managed care regulatory agencies are employed by the same health insurance companies whose decisions these IROs are asked to review. A survey of six ERISA proton therapy denial cases tried in federal court leaves little doubt as to why health insurers are eager to promote external review. Even though federal law requires state agencies to assign an IRO for each appeal from a list of authorized, accredited organizations, many times health plans will have language that sends denied patients to a hand-picked, pre-selected IRO.

Conflicts of interest abound in these external medical reviews because, as 2011 research by Marc A. Rodwin, law professor at Suffolk University Law School, published in Health Affairs indicates, “health plans frequently employ independent review organizations to perform utilization reviews, conduct quality assurance, and oversee internal appeals—work that generates more revenue for the organizations than performing medical reviews does.” IROs have every incentive to rule in favor of plans. Often IRO external reviewer reports rely on the same outdated medical literature cited by the insurance company whose decision is under review.
  Pages: 1 - 2 - 3 - 4 >>

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Alle Gesundheitsdienstleister-Tools anzeigen
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich auf DOTmed bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2019, Inc.